chr15:68050103-68106527 |
chr15:68054388 |
rs884202 |
MAP2K5 |
Restless legs syndrome |
intron |
1.17e-05 |
GWASdb |
| chr15:68050103-68106527 |
chr15:68054996 |
rs868037 |
MAP2K5 |
Type 2 diabetes |
intron |
0.000211 |
GWASdb |
| chr15:68050103-68106527 |
chr15:68058903 |
rs11071959 |
MAP2K5 |
F-cell distribution |
intron |
9.89e-06 |
GWASdb |
| chr15:68050103-68106527 |
chr15:68060389 |
rs745213 |
MAP2K5 |
Orofacial clefts |
intron |
8.65e-05 |
GWASdb |
| chr15:68050103-68106527 |
chr15:68072075 |
rs4489954 |
MAP2K5 |
Type 2 diabetes |
intron |
0.00091 |
GWASdb |
| chr15:68050103-68106527 |
chr15:68072075 |
rs4489954 |
MAP2K5 |
Restless legs syndrome |
intron |
2.68e-15 |
GWASdb |
| chr15:68050103-68106527 |
chr15:68072275 |
rs3784709 |
MAP2K5 |
Type 2 diabetes |
intron |
0.000383 |
GWASdb |
| chr15:68050103-68106527 |
chr15:68072275 |
rs3784709 |
MAP2K5 |
Restless legs syndrome |
intron |
4.06e-16 |
GWASdb |
| chr15:68050103-68106527 |
chr15:68076533 |
rs12902904 |
MAP2K5 |
Blood pressure, CVD RF and other traits (body mass index (BMI), waist:hip ratio, renin activity in plasma, aldosterone concentration in plasma, BNP levels in plasma, alcohol consumption) |
intron |
0.000773 |
GWASdb |
| chr15:68050103-68106527 |
chr15:68080886 |
rs4776970 |
MAP2K5 |
Body mass index |
intron |
2e-09 |
GWASdb |
| chr15:68050103-68106527 |
chr15:68080886 |
rs4776970 |
MAP2K5 |
Body mass index |
intron |
3e-07 |
GWASdb |
| chr15:68050103-68106527 |
chr15:68086838 |
rs2241423 |
MAP2K5 |
Body mass index |
intron |
1e-18 |
GWASdb |
| chr15:68050103-68106527 |
chr15:68086838 |
rs2241423 |
MAP2K5 |
Body mass index |
intron |
6.02e-07 |
GWASdb |
| chr15:68050103-68106527 |
chr15:68086838 |
rs2241423 |
MAP2K5 |
Body mass index |
intron |
1.19e-18 |
GWASdb |
| chr15:68050103-68106527 |
chr15:68090700 |
rs11856999 |
MAP2K5 |
Orofacial clefts |
intron |
6.34e-05 |
GWASdb |
| chr15:68050103-68106527 |
chr15:68095085 |
rs1026732 |
MAP2K5 |
Type 2 diabetes |
intron |
0.000377 |
GWASdb |
| chr15:68050103-68106527 |
chr15:68095085 |
rs1026732 |
MAP2K5 |
Restless legs syndrome |
intron |
6.09e-17 |
GWASdb |
| chr15:68050103-68106527 |
chr15:68103206 |
rs6494696 |
NA |
Type 2 diabetes |
NA |
0.00047 |
GWASdb |
| chr15:68050103-68106527 |
chr15:68103206 |
rs6494696 |
NA |
Restless legs syndrome |
NA |
2e-16 |
GWASdb |
| chr15:68049964-68106690 |
chr15:68054388 |
rs884202 |
MAP2K5 |
Restless legs syndrome |
intron |
1.17e-05 |
GWASdb |
| chr15:68049964-68106690 |
chr15:68054996 |
rs868037 |
MAP2K5 |
Type 2 diabetes |
intron |
0.000211 |
GWASdb |
| chr15:68049964-68106690 |
chr15:68058903 |
rs11071959 |
MAP2K5 |
F-cell distribution |
intron |
9.89e-06 |
GWASdb |
| chr15:68049964-68106690 |
chr15:68060389 |
rs745213 |
MAP2K5 |
Orofacial clefts |
intron |
8.65e-05 |
GWASdb |
| chr15:68049964-68106690 |
chr15:68072075 |
rs4489954 |
MAP2K5 |
Type 2 diabetes |
intron |
0.00091 |
GWASdb |
| chr15:68049964-68106690 |
chr15:68072075 |
rs4489954 |
MAP2K5 |
Restless legs syndrome |
intron |
2.68e-15 |
GWASdb |
| chr15:68049964-68106690 |
chr15:68072275 |
rs3784709 |
MAP2K5 |
Type 2 diabetes |
intron |
0.000383 |
GWASdb |
| chr15:68049964-68106690 |
chr15:68072275 |
rs3784709 |
MAP2K5 |
Restless legs syndrome |
intron |
4.06e-16 |
GWASdb |
| chr15:68049964-68106690 |
chr15:68076533 |
rs12902904 |
MAP2K5 |
Blood pressure, CVD RF and other traits (body mass index (BMI), waist:hip ratio, renin activity in plasma, aldosterone concentration in plasma, BNP levels in plasma, alcohol consumption) |
intron |
0.000773 |
GWASdb |
| chr15:68049964-68106690 |
chr15:68080886 |
rs4776970 |
MAP2K5 |
Body mass index |
intron |
2e-09 |
GWASdb |
| chr15:68049964-68106690 |
chr15:68080886 |
rs4776970 |
MAP2K5 |
Body mass index |
intron |
3e-07 |
GWASdb |
| chr15:68049964-68106690 |
chr15:68086838 |
rs2241423 |
MAP2K5 |
Body mass index |
intron |
1e-18 |
GWASdb |
| chr15:68049964-68106690 |
chr15:68086838 |
rs2241423 |
MAP2K5 |
Body mass index |
intron |
6.02e-07 |
GWASdb |
| chr15:68049964-68106690 |
chr15:68086838 |
rs2241423 |
MAP2K5 |
Body mass index |
intron |
1.19e-18 |
GWASdb |
| chr15:68049964-68106690 |
chr15:68090700 |
rs11856999 |
MAP2K5 |
Orofacial clefts |
intron |
6.34e-05 |
GWASdb |
| chr15:68049964-68106690 |
chr15:68095085 |
rs1026732 |
MAP2K5 |
Type 2 diabetes |
intron |
0.000377 |
GWASdb |
| chr15:68049964-68106690 |
chr15:68095085 |
rs1026732 |
MAP2K5 |
Restless legs syndrome |
intron |
6.09e-17 |
GWASdb |
| chr15:68049964-68106690 |
chr15:68103206 |
rs6494696 |
NA |
Type 2 diabetes |
NA |
0.00047 |
GWASdb |
| chr15:68049964-68106690 |
chr15:68103206 |
rs6494696 |
NA |
Restless legs syndrome |
NA |
2e-16 |
GWASdb |
| chr15:68073650-68098947 |
chr15:68076533 |
rs12902904 |
MAP2K5 |
Blood pressure, CVD RF and other traits (body mass index (BMI), waist:hip ratio, renin activity in plasma, aldosterone concentration in plasma, BNP levels in plasma, alcohol consumption) |
intron |
0.000773 |
GWASdb |
| chr15:68073650-68098947 |
chr15:68080886 |
rs4776970 |
MAP2K5 |
Body mass index |
intron |
2e-09 |
GWASdb |
| chr15:68073650-68098947 |
chr15:68080886 |
rs4776970 |
MAP2K5 |
Body mass index |
intron |
3e-07 |
GWASdb |
| chr15:68073650-68098947 |
chr15:68086838 |
rs2241423 |
MAP2K5 |
Body mass index |
intron |
1e-18 |
GWASdb |
| chr15:68073650-68098947 |
chr15:68086838 |
rs2241423 |
MAP2K5 |
Body mass index |
intron |
6.02e-07 |
GWASdb |
| chr15:68073650-68098947 |
chr15:68086838 |
rs2241423 |
MAP2K5 |
Body mass index |
intron |
1.19e-18 |
GWASdb |
| chr15:68073650-68098947 |
chr15:68090700 |
rs11856999 |
MAP2K5 |
Orofacial clefts |
intron |
6.34e-05 |
GWASdb |
| chr15:68073650-68098947 |
chr15:68095085 |
rs1026732 |
MAP2K5 |
Type 2 diabetes |
intron |
0.000377 |
GWASdb |
| chr15:68073650-68098947 |
chr15:68095085 |
rs1026732 |
MAP2K5 |
Restless legs syndrome |
intron |
6.09e-17 |
GWASdb |
| chr15:68072747-68077033 |
chr15:68076533 |
rs12902904 |
MAP2K5 |
Blood pressure, CVD RF and other traits (body mass index (BMI), waist:hip ratio, renin activity in plasma, aldosterone concentration in plasma, BNP levels in plasma, alcohol consumption) |
intron |
0.000773 |
GWASdb |
| chr15:68000307-68106023 |
chr15:68016343 |
rs997295 |
MAP2K5 |
Body mass index (males) |
intron |
5.5e-06 |
GWASdb |
| chr15:68000307-68106023 |
chr15:68016343 |
rs997295 |
MAP2K5 |
Body mass index |
intron |
1.43e-08 |
GWASdb |
| chr15:68000307-68106023 |
chr15:68036852 |
rs12593813 |
MAP2K5 |
Restless legs syndrome |
intron |
1e-15 |
GWASdb |
| chr15:68000307-68106023 |
chr15:68036852 |
rs12593813 |
MAP2K5 |
Restless legs syndrome |
intron |
1e-22 |
GWASdb |
| chr15:68000307-68106023 |
chr15:68037578 |
rs11635424 |
MAP2K5 |
Restless legs syndrome |
intron |
3.65e-16 |
GWASdb |
| chr15:68000307-68106023 |
chr15:68043057 |
rs8028313 |
MAP2K5 |
Obesity |
intron |
1e-11 |
GWASdb |
| chr15:68000307-68106023 |
chr15:68043057 |
rs8028313 |
MAP2K5 |
Obesity |
intron |
6e-13 |
GWASdb |
| chr15:68000307-68106023 |
chr15:68054388 |
rs884202 |
MAP2K5 |
Restless legs syndrome |
intron |
1.17e-05 |
GWASdb |
| chr15:68000307-68106023 |
chr15:68054996 |
rs868037 |
MAP2K5 |
Type 2 diabetes |
intron |
0.000211 |
GWASdb |
| chr15:68000307-68106023 |
chr15:68058903 |
rs11071959 |
MAP2K5 |
F-cell distribution |
intron |
9.89e-06 |
GWASdb |
| chr15:68000307-68106023 |
chr15:68060389 |
rs745213 |
MAP2K5 |
Orofacial clefts |
intron |
8.65e-05 |
GWASdb |
| chr15:68000307-68106023 |
chr15:68072075 |
rs4489954 |
MAP2K5 |
Type 2 diabetes |
intron |
0.00091 |
GWASdb |
| chr15:68000307-68106023 |
chr15:68072075 |
rs4489954 |
MAP2K5 |
Restless legs syndrome |
intron |
2.68e-15 |
GWASdb |
| chr15:68000307-68106023 |
chr15:68072275 |
rs3784709 |
MAP2K5 |
Type 2 diabetes |
intron |
0.000383 |
GWASdb |
| chr15:68000307-68106023 |
chr15:68072275 |
rs3784709 |
MAP2K5 |
Restless legs syndrome |
intron |
4.06e-16 |
GWASdb |
| chr15:68000307-68106023 |
chr15:68076533 |
rs12902904 |
MAP2K5 |
Blood pressure, CVD RF and other traits (body mass index (BMI), waist:hip ratio, renin activity in plasma, aldosterone concentration in plasma, BNP levels in plasma, alcohol consumption) |
intron |
0.000773 |
GWASdb |
| chr15:68000307-68106023 |
chr15:68080886 |
rs4776970 |
MAP2K5 |
Body mass index |
intron |
2e-09 |
GWASdb |
| chr15:68000307-68106023 |
chr15:68080886 |
rs4776970 |
MAP2K5 |
Body mass index |
intron |
3e-07 |
GWASdb |
| chr15:68000307-68106023 |
chr15:68086838 |
rs2241423 |
MAP2K5 |
Body mass index |
intron |
1e-18 |
GWASdb |
| chr15:68000307-68106023 |
chr15:68086838 |
rs2241423 |
MAP2K5 |
Body mass index |
intron |
6.02e-07 |
GWASdb |
| chr15:68000307-68106023 |
chr15:68086838 |
rs2241423 |
MAP2K5 |
Body mass index |
intron |
1.19e-18 |
GWASdb |
| chr15:68000307-68106023 |
chr15:68090700 |
rs11856999 |
MAP2K5 |
Orofacial clefts |
intron |
6.34e-05 |
GWASdb |
| chr15:68000307-68106023 |
chr15:68095085 |
rs1026732 |
MAP2K5 |
Type 2 diabetes |
intron |
0.000377 |
GWASdb |
| chr15:68000307-68106023 |
chr15:68095085 |
rs1026732 |
MAP2K5 |
Restless legs syndrome |
intron |
6.09e-17 |
GWASdb |
| chr15:68000307-68106023 |
chr15:68103206 |
rs6494696 |
NA |
Type 2 diabetes |
NA |
0.00047 |
GWASdb |
| chr15:68000307-68106023 |
chr15:68103206 |
rs6494696 |
NA |
Restless legs syndrome |
NA |
2e-16 |
GWASdb |
| chr15:68033341-68098938 |
chr15:68036852 |
rs12593813 |
MAP2K5 |
Restless legs syndrome |
intron |
1e-15 |
GWASdb |
| chr15:68033341-68098938 |
chr15:68036852 |
rs12593813 |
MAP2K5 |
Restless legs syndrome |
intron |
1e-22 |
GWASdb |
| chr15:68033341-68098938 |
chr15:68037578 |
rs11635424 |
MAP2K5 |
Restless legs syndrome |
intron |
3.65e-16 |
GWASdb |
| chr15:68033341-68098938 |
chr15:68043057 |
rs8028313 |
MAP2K5 |
Obesity |
intron |
1e-11 |
GWASdb |
| chr15:68033341-68098938 |
chr15:68043057 |
rs8028313 |
MAP2K5 |
Obesity |
intron |
6e-13 |
GWASdb |
| chr15:68033341-68098938 |
chr15:68054388 |
rs884202 |
MAP2K5 |
Restless legs syndrome |
intron |
1.17e-05 |
GWASdb |
| chr15:68033341-68098938 |
chr15:68054996 |
rs868037 |
MAP2K5 |
Type 2 diabetes |
intron |
0.000211 |
GWASdb |
| chr15:68033341-68098938 |
chr15:68058903 |
rs11071959 |
MAP2K5 |
F-cell distribution |
intron |
9.89e-06 |
GWASdb |
| chr15:68033341-68098938 |
chr15:68060389 |
rs745213 |
MAP2K5 |
Orofacial clefts |
intron |
8.65e-05 |
GWASdb |
| chr15:68033341-68098938 |
chr15:68072075 |
rs4489954 |
MAP2K5 |
Type 2 diabetes |
intron |
0.00091 |
GWASdb |
| chr15:68033341-68098938 |
chr15:68072075 |
rs4489954 |
MAP2K5 |
Restless legs syndrome |
intron |
2.68e-15 |
GWASdb |
| chr15:68033341-68098938 |
chr15:68072275 |
rs3784709 |
MAP2K5 |
Type 2 diabetes |
intron |
0.000383 |
GWASdb |
| chr15:68033341-68098938 |
chr15:68072275 |
rs3784709 |
MAP2K5 |
Restless legs syndrome |
intron |
4.06e-16 |
GWASdb |
| chr15:68033341-68098938 |
chr15:68076533 |
rs12902904 |
MAP2K5 |
Blood pressure, CVD RF and other traits (body mass index (BMI), waist:hip ratio, renin activity in plasma, aldosterone concentration in plasma, BNP levels in plasma, alcohol consumption) |
intron |
0.000773 |
GWASdb |
| chr15:68033341-68098938 |
chr15:68080886 |
rs4776970 |
MAP2K5 |
Body mass index |
intron |
2e-09 |
GWASdb |
| chr15:68033341-68098938 |
chr15:68080886 |
rs4776970 |
MAP2K5 |
Body mass index |
intron |
3e-07 |
GWASdb |
| chr15:68033341-68098938 |
chr15:68086838 |
rs2241423 |
MAP2K5 |
Body mass index |
intron |
1e-18 |
GWASdb |
| chr15:68033341-68098938 |
chr15:68086838 |
rs2241423 |
MAP2K5 |
Body mass index |
intron |
6.02e-07 |
GWASdb |
| chr15:68033341-68098938 |
chr15:68086838 |
rs2241423 |
MAP2K5 |
Body mass index |
intron |
1.19e-18 |
GWASdb |
| chr15:68033341-68098938 |
chr15:68090700 |
rs11856999 |
MAP2K5 |
Orofacial clefts |
intron |
6.34e-05 |
GWASdb |
| chr15:68033341-68098938 |
chr15:68095085 |
rs1026732 |
MAP2K5 |
Type 2 diabetes |
intron |
0.000377 |
GWASdb |
| chr15:68033341-68098938 |
chr15:68095085 |
rs1026732 |
MAP2K5 |
Restless legs syndrome |
intron |
6.09e-17 |
GWASdb |
| chr15:68075002-68078307 |
chr15:68076533 |
rs12902904 |
MAP2K5 |
Blood pressure, CVD RF and other traits (body mass index (BMI), waist:hip ratio, renin activity in plasma, aldosterone concentration in plasma, BNP levels in plasma, alcohol consumption) |
intron |
0.000773 |
GWASdb |
| chr15:68130927-68144551 |
chr15:68137843 |
rs16951344 |
NA |
Blood Pressure |
NA |
3.45e-05 |
GWASdb |
| chr15:68130927-68144551 |
chr15:68137843 |
rs16951344 |
NA |
Blood Pressure |
NA |
2.03e-05 |
GWASdb |
| chr15:68130927-68144551 |
chr15:68140162 |
rs4776991 |
NA |
Blood Pressure |
NA |
1.34e-05 |
GWASdb |
| chr15:68130927-68144551 |
chr15:68140162 |
rs4776991 |
NA |
Blood Pressure |
NA |
6.5e-06 |
GWASdb |
| chr15:68128539-68360012 |
chr15:68137843 |
rs16951344 |
NA |
Blood Pressure |
NA |
3.45e-05 |
GWASdb |
| chr15:68128539-68360012 |
chr15:68137843 |
rs16951344 |
NA |
Blood Pressure |
NA |
2.03e-05 |
GWASdb |
| chr15:68128539-68360012 |
chr15:68140162 |
rs4776991 |
NA |
Blood Pressure |
NA |
1.34e-05 |
GWASdb |
| chr15:68128539-68360012 |
chr15:68140162 |
rs4776991 |
NA |
Blood Pressure |
NA |
6.5e-06 |
GWASdb |
| chr15:68128539-68360012 |
chr15:68148862 |
rs4254278 |
NA |
Multiple complex diseases |
NA |
4.04e-05 |
GWASdb |
| chr15:68128539-68360012 |
chr15:68152198 |
rs28573814 |
NA |
Urinary metabolites |
NA |
2.1e-05 |
GWASdb |
| chr15:68128539-68360012 |
chr15:68155710 |
rs4776381 |
NA |
IgE levels in asthmatics (D.f. specific) |
NA |
1.54e-05 |
GWASdb |
| chr15:68128539-68360012 |
chr15:68155710 |
rs4776381 |
NA |
IgE levels in asthmatics (D.p. specific) |
NA |
4.92e-05 |
GWASdb |
| chr15:68128539-68360012 |
chr15:68157881 |
rs4306451 |
NA |
Cognitive test performance |
NA |
4.9e-05 |
GWASdb |
| chr15:68128539-68360012 |
chr15:68163774 |
rs11071966 |
NA |
Cognitive test performance |
NA |
8.12e-05 |
GWASdb |
| chr15:68128539-68360012 |
chr15:68166930 |
rs387325 |
NA |
Cognitive test performance |
NA |
2.57e-05 |
GWASdb |
| chr15:68128539-68360012 |
chr15:68198523 |
rs450466 |
NA |
Cognitive test performance |
NA |
7.4e-06 |
GWASdb |
| chr15:68128539-68360012 |
chr15:68198622 |
rs430610 |
NA |
Cognitive test performance |
NA |
5.21e-06 |
GWASdb |
| chr15:68128539-68360012 |
chr15:68198911 |
rs448720 |
NA |
Cognitive performance |
NA |
5e-06 |
GWASdb |
| chr15:68128539-68360012 |
chr15:68270380 |
rs338344 |
NA |
Response to taxane treatment (placlitaxel) |
NA |
0.000661 |
GWASdb |
| chr15:68128539-68360012 |
chr15:68294598 |
rs1532113 |
NA |
Lung function (forced vital capacity) |
NA |
0.000415 |
GWASdb |
| chr15:68128539-68360012 |
chr15:68302144 |
rs16951552 |
NA |
Multiple complex diseases |
NA |
0.000183 |
GWASdb |
| chr15:68128539-68360012 |
chr15:68317451 |
rs16951575 |
NA |
Multiple complex diseases |
NA |
0.000254 |
GWASdb |
| chr15:68128539-68360012 |
chr15:68329444 |
rs11071975 |
NA |
Recombination rate |
NA |
0.000828 |
GWASdb |
| chr15:68128539-68360012 |
chr15:68304789 |
rs7174755 |
ITGA11 |
Major depressive disorder |
intron_variant |
9e-07 |
GWAS_Catalog |
| chr15:68128539-68360012 |
chr15:68304789 |
rs7174755 |
ITGA11 |
Major depressive disorder |
intron_variant |
3e-07 |
GWAS_Catalog |
| chr15:68128539-68360012 |
chr15:68343437 |
rs1563894 |
ITGA11 |
Systolic blood pressure |
intron_variant |
3e-08 |
GWAS_Catalog |
| chr15:68128539-68360012 |
chr15:68330009 |
rs7179228 |
ITGA11 |
Systolic blood pressure |
intron_variant |
1e-07 |
GWAS_Catalog |
| chr15:68132425-68156877 |
chr15:68137843 |
rs16951344 |
NA |
Blood Pressure |
NA |
3.45e-05 |
GWASdb |
| chr15:68132425-68156877 |
chr15:68137843 |
rs16951344 |
NA |
Blood Pressure |
NA |
2.03e-05 |
GWASdb |
| chr15:68132425-68156877 |
chr15:68140162 |
rs4776991 |
NA |
Blood Pressure |
NA |
1.34e-05 |
GWASdb |
| chr15:68132425-68156877 |
chr15:68140162 |
rs4776991 |
NA |
Blood Pressure |
NA |
6.5e-06 |
GWASdb |
| chr15:68132425-68156877 |
chr15:68148862 |
rs4254278 |
NA |
Multiple complex diseases |
NA |
4.04e-05 |
GWASdb |
| chr15:68132425-68156877 |
chr15:68152198 |
rs28573814 |
NA |
Urinary metabolites |
NA |
2.1e-05 |
GWASdb |
| chr15:68132425-68156877 |
chr15:68155710 |
rs4776381 |
NA |
IgE levels in asthmatics (D.f. specific) |
NA |
1.54e-05 |
GWASdb |
| chr15:68132425-68156877 |
chr15:68155710 |
rs4776381 |
NA |
IgE levels in asthmatics (D.p. specific) |
NA |
4.92e-05 |
GWASdb |
| chr15:68130835-68158906 |
chr15:68137843 |
rs16951344 |
NA |
Blood Pressure |
NA |
3.45e-05 |
GWASdb |
| chr15:68130835-68158906 |
chr15:68137843 |
rs16951344 |
NA |
Blood Pressure |
NA |
2.03e-05 |
GWASdb |
| chr15:68130835-68158906 |
chr15:68140162 |
rs4776991 |
NA |
Blood Pressure |
NA |
1.34e-05 |
GWASdb |
| chr15:68130835-68158906 |
chr15:68140162 |
rs4776991 |
NA |
Blood Pressure |
NA |
6.5e-06 |
GWASdb |
| chr15:68130835-68158906 |
chr15:68148862 |
rs4254278 |
NA |
Multiple complex diseases |
NA |
4.04e-05 |
GWASdb |
| chr15:68130835-68158906 |
chr15:68152198 |
rs28573814 |
NA |
Urinary metabolites |
NA |
2.1e-05 |
GWASdb |
| chr15:68130835-68158906 |
chr15:68155710 |
rs4776381 |
NA |
IgE levels in asthmatics (D.f. specific) |
NA |
1.54e-05 |
GWASdb |
| chr15:68130835-68158906 |
chr15:68155710 |
rs4776381 |
NA |
IgE levels in asthmatics (D.p. specific) |
NA |
4.92e-05 |
GWASdb |
| chr15:68130835-68158906 |
chr15:68157881 |
rs4306451 |
NA |
Cognitive test performance |
NA |
4.9e-05 |
GWASdb |
| chr15:68130948-68159447 |
chr15:68137843 |
rs16951344 |
NA |
Blood Pressure |
NA |
3.45e-05 |
GWASdb |
| chr15:68130948-68159447 |
chr15:68137843 |
rs16951344 |
NA |
Blood Pressure |
NA |
2.03e-05 |
GWASdb |
| chr15:68130948-68159447 |
chr15:68140162 |
rs4776991 |
NA |
Blood Pressure |
NA |
1.34e-05 |
GWASdb |
| chr15:68130948-68159447 |
chr15:68140162 |
rs4776991 |
NA |
Blood Pressure |
NA |
6.5e-06 |
GWASdb |
| chr15:68130948-68159447 |
chr15:68148862 |
rs4254278 |
NA |
Multiple complex diseases |
NA |
4.04e-05 |
GWASdb |
| chr15:68130948-68159447 |
chr15:68152198 |
rs28573814 |
NA |
Urinary metabolites |
NA |
2.1e-05 |
GWASdb |
| chr15:68130948-68159447 |
chr15:68155710 |
rs4776381 |
NA |
IgE levels in asthmatics (D.f. specific) |
NA |
1.54e-05 |
GWASdb |
| chr15:68130948-68159447 |
chr15:68155710 |
rs4776381 |
NA |
IgE levels in asthmatics (D.p. specific) |
NA |
4.92e-05 |
GWASdb |
| chr15:68130948-68159447 |
chr15:68157881 |
rs4306451 |
NA |
Cognitive test performance |
NA |
4.9e-05 |
GWASdb |
| chr15:68154322-68185969 |
chr15:68155710 |
rs4776381 |
NA |
IgE levels in asthmatics (D.f. specific) |
NA |
1.54e-05 |
GWASdb |
| chr15:68154322-68185969 |
chr15:68155710 |
rs4776381 |
NA |
IgE levels in asthmatics (D.p. specific) |
NA |
4.92e-05 |
GWASdb |
| chr15:68154322-68185969 |
chr15:68157881 |
rs4306451 |
NA |
Cognitive test performance |
NA |
4.9e-05 |
GWASdb |
| chr15:68154322-68185969 |
chr15:68163774 |
rs11071966 |
NA |
Cognitive test performance |
NA |
8.12e-05 |
GWASdb |
| chr15:68154322-68185969 |
chr15:68166930 |
rs387325 |
NA |
Cognitive test performance |
NA |
2.57e-05 |
GWASdb |
| chr15:68151409-68185914 |
chr15:68152198 |
rs28573814 |
NA |
Urinary metabolites |
NA |
2.1e-05 |
GWASdb |
| chr15:68151409-68185914 |
chr15:68155710 |
rs4776381 |
NA |
IgE levels in asthmatics (D.f. specific) |
NA |
1.54e-05 |
GWASdb |
| chr15:68151409-68185914 |
chr15:68155710 |
rs4776381 |
NA |
IgE levels in asthmatics (D.p. specific) |
NA |
4.92e-05 |
GWASdb |
| chr15:68151409-68185914 |
chr15:68157881 |
rs4306451 |
NA |
Cognitive test performance |
NA |
4.9e-05 |
GWASdb |
| chr15:68151409-68185914 |
chr15:68163774 |
rs11071966 |
NA |
Cognitive test performance |
NA |
8.12e-05 |
GWASdb |
| chr15:68151409-68185914 |
chr15:68166930 |
rs387325 |
NA |
Cognitive test performance |
NA |
2.57e-05 |
GWASdb |
| chr15:68151442-68255122 |
chr15:68152198 |
rs28573814 |
NA |
Urinary metabolites |
NA |
2.1e-05 |
GWASdb |
| chr15:68151442-68255122 |
chr15:68155710 |
rs4776381 |
NA |
IgE levels in asthmatics (D.f. specific) |
NA |
1.54e-05 |
GWASdb |
| chr15:68151442-68255122 |
chr15:68155710 |
rs4776381 |
NA |
IgE levels in asthmatics (D.p. specific) |
NA |
4.92e-05 |
GWASdb |
| chr15:68151442-68255122 |
chr15:68157881 |
rs4306451 |
NA |
Cognitive test performance |
NA |
4.9e-05 |
GWASdb |
| chr15:68151442-68255122 |
chr15:68163774 |
rs11071966 |
NA |
Cognitive test performance |
NA |
8.12e-05 |
GWASdb |
| chr15:68151442-68255122 |
chr15:68166930 |
rs387325 |
NA |
Cognitive test performance |
NA |
2.57e-05 |
GWASdb |
| chr15:68151442-68255122 |
chr15:68198523 |
rs450466 |
NA |
Cognitive test performance |
NA |
7.4e-06 |
GWASdb |
| chr15:68151442-68255122 |
chr15:68198622 |
rs430610 |
NA |
Cognitive test performance |
NA |
5.21e-06 |
GWASdb |
| chr15:68151442-68255122 |
chr15:68198911 |
rs448720 |
NA |
Cognitive performance |
NA |
5e-06 |
GWASdb |
| chr15:68151290-68186016 |
chr15:68152198 |
rs28573814 |
NA |
Urinary metabolites |
NA |
2.1e-05 |
GWASdb |
| chr15:68151290-68186016 |
chr15:68155710 |
rs4776381 |
NA |
IgE levels in asthmatics (D.f. specific) |
NA |
1.54e-05 |
GWASdb |
| chr15:68151290-68186016 |
chr15:68155710 |
rs4776381 |
NA |
IgE levels in asthmatics (D.p. specific) |
NA |
4.92e-05 |
GWASdb |
| chr15:68151290-68186016 |
chr15:68157881 |
rs4306451 |
NA |
Cognitive test performance |
NA |
4.9e-05 |
GWASdb |
| chr15:68151290-68186016 |
chr15:68163774 |
rs11071966 |
NA |
Cognitive test performance |
NA |
8.12e-05 |
GWASdb |
| chr15:68151290-68186016 |
chr15:68166930 |
rs387325 |
NA |
Cognitive test performance |
NA |
2.57e-05 |
GWASdb |
| chr15:68154458-68185971 |
chr15:68155710 |
rs4776381 |
NA |
IgE levels in asthmatics (D.f. specific) |
NA |
1.54e-05 |
GWASdb |
| chr15:68154458-68185971 |
chr15:68155710 |
rs4776381 |
NA |
IgE levels in asthmatics (D.p. specific) |
NA |
4.92e-05 |
GWASdb |
| chr15:68154458-68185971 |
chr15:68157881 |
rs4306451 |
NA |
Cognitive test performance |
NA |
4.9e-05 |
GWASdb |
| chr15:68154458-68185971 |
chr15:68163774 |
rs11071966 |
NA |
Cognitive test performance |
NA |
8.12e-05 |
GWASdb |
| chr15:68154458-68185971 |
chr15:68166930 |
rs387325 |
NA |
Cognitive test performance |
NA |
2.57e-05 |
GWASdb |
| chr15:68154782-68182146 |
chr15:68155710 |
rs4776381 |
NA |
IgE levels in asthmatics (D.f. specific) |
NA |
1.54e-05 |
GWASdb |
| chr15:68154782-68182146 |
chr15:68155710 |
rs4776381 |
NA |
IgE levels in asthmatics (D.p. specific) |
NA |
4.92e-05 |
GWASdb |
| chr15:68154782-68182146 |
chr15:68157881 |
rs4306451 |
NA |
Cognitive test performance |
NA |
4.9e-05 |
GWASdb |
| chr15:68154782-68182146 |
chr15:68163774 |
rs11071966 |
NA |
Cognitive test performance |
NA |
8.12e-05 |
GWASdb |
| chr15:68154782-68182146 |
chr15:68166930 |
rs387325 |
NA |
Cognitive test performance |
NA |
2.57e-05 |
GWASdb |
| chr15:68152091-68255128 |
chr15:68152198 |
rs28573814 |
NA |
Urinary metabolites |
NA |
2.1e-05 |
GWASdb |
| chr15:68152091-68255128 |
chr15:68155710 |
rs4776381 |
NA |
IgE levels in asthmatics (D.f. specific) |
NA |
1.54e-05 |
GWASdb |
| chr15:68152091-68255128 |
chr15:68155710 |
rs4776381 |
NA |
IgE levels in asthmatics (D.p. specific) |
NA |
4.92e-05 |
GWASdb |
| chr15:68152091-68255128 |
chr15:68157881 |
rs4306451 |
NA |
Cognitive test performance |
NA |
4.9e-05 |
GWASdb |
| chr15:68152091-68255128 |
chr15:68163774 |
rs11071966 |
NA |
Cognitive test performance |
NA |
8.12e-05 |
GWASdb |
| chr15:68152091-68255128 |
chr15:68166930 |
rs387325 |
NA |
Cognitive test performance |
NA |
2.57e-05 |
GWASdb |
| chr15:68152091-68255128 |
chr15:68198523 |
rs450466 |
NA |
Cognitive test performance |
NA |
7.4e-06 |
GWASdb |
| chr15:68152091-68255128 |
chr15:68198622 |
rs430610 |
NA |
Cognitive test performance |
NA |
5.21e-06 |
GWASdb |
| chr15:68152091-68255128 |
chr15:68198911 |
rs448720 |
NA |
Cognitive performance |
NA |
5e-06 |
GWASdb |
| chr15:68130945-68185912 |
chr15:68137843 |
rs16951344 |
NA |
Blood Pressure |
NA |
3.45e-05 |
GWASdb |
| chr15:68130945-68185912 |
chr15:68137843 |
rs16951344 |
NA |
Blood Pressure |
NA |
2.03e-05 |
GWASdb |
| chr15:68130945-68185912 |
chr15:68140162 |
rs4776991 |
NA |
Blood Pressure |
NA |
1.34e-05 |
GWASdb |
| chr15:68130945-68185912 |
chr15:68140162 |
rs4776991 |
NA |
Blood Pressure |
NA |
6.5e-06 |
GWASdb |
| chr15:68130945-68185912 |
chr15:68148862 |
rs4254278 |
NA |
Multiple complex diseases |
NA |
4.04e-05 |
GWASdb |
| chr15:68130945-68185912 |
chr15:68152198 |
rs28573814 |
NA |
Urinary metabolites |
NA |
2.1e-05 |
GWASdb |
| chr15:68130945-68185912 |
chr15:68155710 |
rs4776381 |
NA |
IgE levels in asthmatics (D.f. specific) |
NA |
1.54e-05 |
GWASdb |
| chr15:68130945-68185912 |
chr15:68155710 |
rs4776381 |
NA |
IgE levels in asthmatics (D.p. specific) |
NA |
4.92e-05 |
GWASdb |
| chr15:68130945-68185912 |
chr15:68157881 |
rs4306451 |
NA |
Cognitive test performance |
NA |
4.9e-05 |
GWASdb |
| chr15:68130945-68185912 |
chr15:68163774 |
rs11071966 |
NA |
Cognitive test performance |
NA |
8.12e-05 |
GWASdb |
| chr15:68130945-68185912 |
chr15:68166930 |
rs387325 |
NA |
Cognitive test performance |
NA |
2.57e-05 |
GWASdb |
| chr15:68151529-68184675 |
chr15:68152198 |
rs28573814 |
NA |
Urinary metabolites |
NA |
2.1e-05 |
GWASdb |
| chr15:68151529-68184675 |
chr15:68155710 |
rs4776381 |
NA |
IgE levels in asthmatics (D.f. specific) |
NA |
1.54e-05 |
GWASdb |
| chr15:68151529-68184675 |
chr15:68155710 |
rs4776381 |
NA |
IgE levels in asthmatics (D.p. specific) |
NA |
4.92e-05 |
GWASdb |
| chr15:68151529-68184675 |
chr15:68157881 |
rs4306451 |
NA |
Cognitive test performance |
NA |
4.9e-05 |
GWASdb |
| chr15:68151529-68184675 |
chr15:68163774 |
rs11071966 |
NA |
Cognitive test performance |
NA |
8.12e-05 |
GWASdb |
| chr15:68151529-68184675 |
chr15:68166930 |
rs387325 |
NA |
Cognitive test performance |
NA |
2.57e-05 |
GWASdb |
| chr15:68125905-68159244 |
chr15:68128117 |
rs12898654 |
NA |
Type 2 diabetes |
NA |
0.000593 |
GWASdb |
| chr15:68125905-68159244 |
chr15:68128117 |
rs12898654 |
NA |
Diabetes (gestational) |
NA |
4.37e-06 |
GWASdb |
| chr15:68125905-68159244 |
chr15:68137843 |
rs16951344 |
NA |
Blood Pressure |
NA |
3.45e-05 |
GWASdb |
| chr15:68125905-68159244 |
chr15:68137843 |
rs16951344 |
NA |
Blood Pressure |
NA |
2.03e-05 |
GWASdb |
| chr15:68125905-68159244 |
chr15:68140162 |
rs4776991 |
NA |
Blood Pressure |
NA |
1.34e-05 |
GWASdb |
| chr15:68125905-68159244 |
chr15:68140162 |
rs4776991 |
NA |
Blood Pressure |
NA |
6.5e-06 |
GWASdb |
| chr15:68125905-68159244 |
chr15:68148862 |
rs4254278 |
NA |
Multiple complex diseases |
NA |
4.04e-05 |
GWASdb |
| chr15:68125905-68159244 |
chr15:68152198 |
rs28573814 |
NA |
Urinary metabolites |
NA |
2.1e-05 |
GWASdb |
| chr15:68125905-68159244 |
chr15:68155710 |
rs4776381 |
NA |
IgE levels in asthmatics (D.f. specific) |
NA |
1.54e-05 |
GWASdb |
| chr15:68125905-68159244 |
chr15:68155710 |
rs4776381 |
NA |
IgE levels in asthmatics (D.p. specific) |
NA |
4.92e-05 |
GWASdb |
| chr15:68125905-68159244 |
chr15:68157881 |
rs4306451 |
NA |
Cognitive test performance |
NA |
4.9e-05 |
GWASdb |
| chr15:68125422-68156694 |
chr15:68128117 |
rs12898654 |
NA |
Type 2 diabetes |
NA |
0.000593 |
GWASdb |
| chr15:68125422-68156694 |
chr15:68128117 |
rs12898654 |
NA |
Diabetes (gestational) |
NA |
4.37e-06 |
GWASdb |
| chr15:68125422-68156694 |
chr15:68137843 |
rs16951344 |
NA |
Blood Pressure |
NA |
3.45e-05 |
GWASdb |
| chr15:68125422-68156694 |
chr15:68137843 |
rs16951344 |
NA |
Blood Pressure |
NA |
2.03e-05 |
GWASdb |
| chr15:68125422-68156694 |
chr15:68140162 |
rs4776991 |
NA |
Blood Pressure |
NA |
1.34e-05 |
GWASdb |
| chr15:68125422-68156694 |
chr15:68140162 |
rs4776991 |
NA |
Blood Pressure |
NA |
6.5e-06 |
GWASdb |
| chr15:68125422-68156694 |
chr15:68148862 |
rs4254278 |
NA |
Multiple complex diseases |
NA |
4.04e-05 |
GWASdb |
| chr15:68125422-68156694 |
chr15:68152198 |
rs28573814 |
NA |
Urinary metabolites |
NA |
2.1e-05 |
GWASdb |
| chr15:68125422-68156694 |
chr15:68155710 |
rs4776381 |
NA |
IgE levels in asthmatics (D.f. specific) |
NA |
1.54e-05 |
GWASdb |
| chr15:68125422-68156694 |
chr15:68155710 |
rs4776381 |
NA |
IgE levels in asthmatics (D.p. specific) |
NA |
4.92e-05 |
GWASdb |
| chr15:68175583-68221418 |
chr15:68198523 |
rs450466 |
NA |
Cognitive test performance |
NA |
7.4e-06 |
GWASdb |
| chr15:68175583-68221418 |
chr15:68198622 |
rs430610 |
NA |
Cognitive test performance |
NA |
5.21e-06 |
GWASdb |
| chr15:68175583-68221418 |
chr15:68198911 |
rs448720 |
NA |
Cognitive performance |
NA |
5e-06 |
GWASdb |
| chr15:68198642-68251500 |
chr15:68198911 |
rs448720 |
NA |
Cognitive performance |
NA |
5e-06 |
GWASdb |
| chr15:68052382-68134337 |
chr15:68054388 |
rs884202 |
MAP2K5 |
Restless legs syndrome |
intron |
1.17e-05 |
GWASdb |
| chr15:68052382-68134337 |
chr15:68054996 |
rs868037 |
MAP2K5 |
Type 2 diabetes |
intron |
0.000211 |
GWASdb |
| chr15:68052382-68134337 |
chr15:68058903 |
rs11071959 |
MAP2K5 |
F-cell distribution |
intron |
9.89e-06 |
GWASdb |
| chr15:68052382-68134337 |
chr15:68060389 |
rs745213 |
MAP2K5 |
Orofacial clefts |
intron |
8.65e-05 |
GWASdb |
| chr15:68052382-68134337 |
chr15:68072075 |
rs4489954 |
MAP2K5 |
Type 2 diabetes |
intron |
0.00091 |
GWASdb |
| chr15:68052382-68134337 |
chr15:68072075 |
rs4489954 |
MAP2K5 |
Restless legs syndrome |
intron |
2.68e-15 |
GWASdb |
| chr15:68052382-68134337 |
chr15:68072275 |
rs3784709 |
MAP2K5 |
Type 2 diabetes |
intron |
0.000383 |
GWASdb |
| chr15:68052382-68134337 |
chr15:68072275 |
rs3784709 |
MAP2K5 |
Restless legs syndrome |
intron |
4.06e-16 |
GWASdb |
| chr15:68052382-68134337 |
chr15:68076533 |
rs12902904 |
MAP2K5 |
Blood pressure, CVD RF and other traits (body mass index (BMI), waist:hip ratio, renin activity in plasma, aldosterone concentration in plasma, BNP levels in plasma, alcohol consumption) |
intron |
0.000773 |
GWASdb |
| chr15:68052382-68134337 |
chr15:68080886 |
rs4776970 |
MAP2K5 |
Body mass index |
intron |
2e-09 |
GWASdb |
| chr15:68052382-68134337 |
chr15:68080886 |
rs4776970 |
MAP2K5 |
Body mass index |
intron |
3e-07 |
GWASdb |
| chr15:68052382-68134337 |
chr15:68086838 |
rs2241423 |
MAP2K5 |
Body mass index |
intron |
1e-18 |
GWASdb |
| chr15:68052382-68134337 |
chr15:68086838 |
rs2241423 |
MAP2K5 |
Body mass index |
intron |
6.02e-07 |
GWASdb |
| chr15:68052382-68134337 |
chr15:68086838 |
rs2241423 |
MAP2K5 |
Body mass index |
intron |
1.19e-18 |
GWASdb |
| chr15:68052382-68134337 |
chr15:68090700 |
rs11856999 |
MAP2K5 |
Orofacial clefts |
intron |
6.34e-05 |
GWASdb |
| chr15:68052382-68134337 |
chr15:68095085 |
rs1026732 |
MAP2K5 |
Type 2 diabetes |
intron |
0.000377 |
GWASdb |
| chr15:68052382-68134337 |
chr15:68095085 |
rs1026732 |
MAP2K5 |
Restless legs syndrome |
intron |
6.09e-17 |
GWASdb |
| chr15:68052382-68134337 |
chr15:68103206 |
rs6494696 |
NA |
Type 2 diabetes |
NA |
0.00047 |
GWASdb |
| chr15:68052382-68134337 |
chr15:68103206 |
rs6494696 |
NA |
Restless legs syndrome |
NA |
2e-16 |
GWASdb |
| chr15:68052382-68134337 |
chr15:68128117 |
rs12898654 |
NA |
Type 2 diabetes |
NA |
0.000593 |
GWASdb |
| chr15:68052382-68134337 |
chr15:68128117 |
rs12898654 |
NA |
Diabetes (gestational) |
NA |
4.37e-06 |
GWASdb |
| chr15:68196028-68240920 |
chr15:68198523 |
rs450466 |
NA |
Cognitive test performance |
NA |
7.4e-06 |
GWASdb |
| chr15:68196028-68240920 |
chr15:68198622 |
rs430610 |
NA |
Cognitive test performance |
NA |
5.21e-06 |
GWASdb |
| chr15:68196028-68240920 |
chr15:68198911 |
rs448720 |
NA |
Cognitive performance |
NA |
5e-06 |
GWASdb |
| chr15:68176284-68209945 |
chr15:68198523 |
rs450466 |
NA |
Cognitive test performance |
NA |
7.4e-06 |
GWASdb |
| chr15:68176284-68209945 |
chr15:68198622 |
rs430610 |
NA |
Cognitive test performance |
NA |
5.21e-06 |
GWASdb |
| chr15:68176284-68209945 |
chr15:68198911 |
rs448720 |
NA |
Cognitive performance |
NA |
5e-06 |
GWASdb |